TED Ted Baker Plc

RNS Number:5148T
Tepnel Life Sciences PLC
01 May 2008








FOR IMMEDIATE RELEASE



Tepnel's preferred supplier agreement with AstraZeneca for DNA extraction
services is extended



Manchester, UK, 1 May 2008 - Tepnel Life Sciences PLC (AIM: TED), the UK-based
international Molecular Diagnostics and Research Products & Services group,
announced today it has extended its global Master Services Agreement with
AstraZeneca, one of the world's leading pharmaceutical companies.



Under the terms of this agreement Tepnel will continue to act as a preferred
supplier to AstraZeneca for DNA extraction services.  By continuing to provide a
high quality service in the market, Tepnel will have the opportunity to compete
for further business with AstraZeneca at volume-related discounts.



Ben Matzilevich, CEO, commented: "Following our very strong financial results
for 2007 we are delighted to announce the extension of our existing agreement
with AstraZeneca.



"Tepnel has been a supplier to AstraZeneca in the area of DNA extraction for a
number of years and this announcement is evidence of the high level of client
service and technical expertise that we are able to deliver. This agreement
further strengthens Tepnel's position in the pharmaceutical industry as one of
Europe's largest providers of DNA extraction services."



                                    - ends -



Enquiries:



Tepnel Life Sciences plc
Ben Matzilevich, CEO

0161 946 2200



Capital MS&L

Mary Clark or Joey Whineray

+44 207 307 5330


Seymour Pierce Limited
Mark Percy
Tel: +44 20 7107 8000









Notes to Editors


About Tepnel Life Sciences plc

Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences
products and services Group with two divisions, Molecular Diagnostics and
Research Products & Services. The Company has laboratories, manufacturing and
operations in the USA, UK and France with over 200 employees. Tepnel provides
test kits, reagents and services to two highly synergistic markets, these being
Molecular Diagnostics and Biomedical Research. The Company's strategy has been
to identify high growth niche opportunities within these multi-billion pound
markets. Tepnel focuses on these niche operations with internally developed
products, patents, expertise and know-how as well as strategic acquisitions, to
develop a leadership position within these defined market segments.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRBRGDSLDXGGIG

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024